Concord Biotech balance sheet

As of Sep 2026

Total assets: ₹2,327cr+15.0% on Sep 2025
Shareholders' equity: ₹2,072cr+13.4% on Sep 2025
Total debt: ₹0.0crNo figure a year before
Cash and investments: ₹446cr+35.2% on Sep 2025

₹ crore except per share

Tap a line for its trend	H1 FY27Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023

Non-current assets
	760	786	792	572	—
	112	78.2	50.1	211	—
	0.0	—	0.6	0.0	—
	0.5	0.4	0.0	0.0	—
	4.7	2.4	2.3	3.6	—
	2.1	1.2	0.5	0.0	—
	4.3	3.6	0.7	2.1	—
	95.3	84.9	18.0	0.0	—
	19.4	6.5	12.6	5.0	—
	115	91.4	30.6	5.0	—
	13.9	5.8	1.8	2.7	—
	24.8	15.9	20.6	8.0	—
	1,036	985	899	804	—
Current assets
	398	326	240	208	—
	438	402	317	244	—
	412	460	522	350	—
	7.5	12.2	0.9	15.1	—
	0.1	1.4	0.3	31.9	—
	0.0	0.0	40.8	0.0	—
	13.8	25.2	15.4	19.4	—
	872	901	896	660	—
	20.9	22.7	15.4	28.5	—
	1,291	1,250	1,135	896	—
	2,327	2,235	2,034	1,701	—
Equity
	10.5	10.5	10.5	10.5	10.5
	2,065	2,007	1,802	1,516	1,280
	2,076	2,017	1,813	1,527	—
	−3.9	−1.9	0.0	—	—
	2,072	2,015	1,813	1,527	—
Liabilities
	1.5	1.4	0.6	1.9	—
	1.5	1.4	0.6	1.9	—
	3.3	3.7	2.8	2.0	—
	48.6	45.4	34.0	28.1	—
	53.4	50.5	37.5	31.9	—
	0.0	0.0	0.4	6.2	—
	112	102	113	94.4	—
	48.3	43.6	43.7	25.8	—
	160	145	157	126	—
	12.4	11.2	5.5	3.9	—
	0.2	0.0	10.1	5.5	—
	28.6	12.3	11.3	6.3	—
	202	169	184	142	—
	255	220	222	174	—
	2,327	2,235	2,034	1,701	—
Trade payables — MSME split
	14.7	14.7	6.0	—	—
	97.4	87.2	107	—	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

CONCORDBIO₹1,230.60

Concord Biotech Ltd.

· Pharma & Health

₹ CrorePeersBIOCON DIVISLAB CAPLIPOINT EMCURE BLUEJET ERIS GRANULES ACUTAASMcap ₹12,874 Cr

View

In ₹ Crore except Per Share As of	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Non-current Assets
+ Property, Plant & Equipment	—	571.7	791.8	785.7	759.6
+ Capital Work-in-Progress	—	211.5	50.1	78.2	111.6
+ Investment Property	—	0.0	0.6	—	0.0
+ Goodwill	—	0.0	0.0	0.4	0.5
+ Other Intangibles	—	3.6	2.3	2.4	4.7
+ Intangibles under Development	—	0.0	0.5	1.2	2.1
+ Investments (Equity Method)	—	2.1	0.7	3.6	4.3
+ Non-current Investments	—	0.0	18.0	84.9	95.3
+ Other Non-current Financial Assets	—	5.0	12.6	6.5	19.4
Non-current Financial Assets	—	5.0	30.6	91.4	114.7
+ Deferred Tax Assets	—	2.7	1.8	5.8	13.9
+ Other Non-current Assets	—	8.0	20.6	15.9	24.8
Total Non-current Assets	—	804.5	899.0	984.6	1,036.3
Current Assets
+ Inventories	—	208.0	239.7	326.4	397.8
+ Current Investments	—	243.7	316.5	402.1	438.1
+ Trade Receivables	—	349.6	521.7	460.2	412.5
+ Cash & Cash Equivalents	—	15.1	0.9	12.2	7.5
+ Other Bank Balances	—	31.9	0.3	1.4	0.1
+ Short-term Loans	—	0.0	40.8	0.0	0.0
+ Other Current Financial Assets	—	19.4	15.4	25.2	13.8
Current Financial Assets	—	659.8	895.6	901.1	872.0
+ Other Current Assets	—	28.5	15.4	22.7	20.9
Total Current Assets	—	896.2	1,135.2	1,250.1	1,290.7
Total Assets	—	1,700.7	2,034.3	2,234.7	2,327.0
Equity
+ Equity Share Capital	10.5	10.5	10.5	10.5	10.5
+ Other Equity / Reserves	1,279.5	1,516.2	1,802.3	2,006.6	2,065.3
Equity — Owners of Parent	—	1,526.6	1,812.7	2,017.1	2,075.8
+ Minority Interest	—	—	0.0	-1.9	-3.9
Total Equity	—	1,526.6	1,812.7	2,015.1	2,071.9
Liabilities
+ Other Non-current Financial Liab	—	1.9	0.6	1.4	1.5
Non-current Financial Liabilities	—	1.9	0.6	1.4	1.5
+ Provisions — Non-current	—	2.0	2.8	3.7	3.3
+ Deferred Tax Liabilities	—	28.1	34.0	45.4	48.6
Non-current Liabilities	—	31.9	37.5	50.5	53.4
+ Borrowings — Current	—	6.2	0.4	0.0	0.0
+ Trade Payables	—	94.4	113.0	101.9	112.1
+ Other Current Financial Liab	—	25.8	43.7	43.6	48.3
Current Financial Liabilities	—	126.5	157.1	145.5	160.4
+ Provisions — Current	—	3.9	5.5	11.2	12.4
+ Current Tax Liabilities	—	5.5	10.1	0.0	0.2
+ Other Current Liabilities	—	6.3	11.3	12.3	28.6
Current Liabilities	—	142.2	184.1	169.1	201.7
Total Liabilities	—	174.1	221.5	219.6	255.1
Total Equity & Liabilities	—	1,700.7	2,034.3	2,234.7	2,327.0
Trade Payables — MSME split
+ Dues to Micro & Small — Current	—	—	6.0	14.7	14.7
+ Dues to Other Creditors — Current	—	—	107.1	87.2	97.4

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.